-
Miami stumble to draw against Cincinnati despite Suarez strike
-
Trump accuses Alaska Democrats of fraud over same-name scandal
-
Bangladesh scrambling as Ganges water treaty to expire
-
Spain mourns after latest train tragedy kills 68
-
England in peril with Rugby League World Cup semi spots at stake
-
Trump's border: quiet, but few people are happy
-
Antonelli ready to rewrite the Formula One record books in Mexico
-
Australian defence chief says China military buildup creating 'pressure' in SE Asia
-
EU, Canada to build 'new chapter' in alliance at Montreal summit
-
No penalty practice? No problem for Man City in shoot-out win
-
Argentine football fan jailed for threats over Di Maria return
-
Microsoft beats expectations fueled by Azure cloud business
-
Liverpool beat Chelsea in League Cup shoot-out, Man City survive scare
-
Chelsea win as Bayern draw with Madrid in Women's Champions League
-
Inter leave it late again in Serie A as AC Milan, Juventus lose
-
Kane watches as Bayern cruise into German Cup last 16
-
Shares in Google owner Alphabet plummet on profit miss, ad slowdown
-
Bayern boss Kompany out of hospital after meningeal irritation
-
Putin hails Elon Musk as 'truly a genius'
-
Shares in Google owner Alphabet sink on profit miss, ad slowdown
-
US stocks eye big tech earnings as Fed holds rates steady
-
Chelsea win as Bayern and Madrid draw in Women's Champions League
-
US Fed holds interest rates steady despite 'too high' inflation
-
Made with munitions from the Falklands War, a 'Chalice of Peace' for the pope
-
Rwanda cannot be blamed for what happens in DR Congo, FM says
-
Pioneering US labor leader Dolores Huerta dies at 96
-
Inter leave it late again in Serie A as Bologna sink AC Milan
-
Italian PM slams 'shameful' release of alleged protest organiser
-
Bolsonaro's escape to the US: How it happened
-
Hollywood producer Kennedy to head LA28 Olympic ceremony plans
-
Russell calls on Scotland to 'kick on' and beat big teams
-
Djokovic wins Basel opener to boost ATP Finals bid
-
Airbus aims for record deliveries despite disappointing quarter
-
US Fed holds interest rates steady despite surging inflation
-
Cuba wins UN vote against US embargo with weakest backing in 30 years
-
Chiefs sign ex-Ravens kicker suspended over sex allegations
-
Real Madrid, La Liga apology over Mbappe shows power of Chinese market
-
Inglis and Carey put Australia in command of South Africa decider
-
From Gaza to Ramallah, Palestinians see little hope in Israeli vote
-
92-year-old US judge handling Maduro case dies
-
US labor leader Dolores Huerta dead: family
-
Perez extends Cadillac deal to 2029
-
Investors turn cautious ahead of tech results, Fed update on rates
-
Arab Israelis proud of high election turnout, uncertain for future
-
'Cruise for life' strands passengers in Cambodia as operator goes bust
-
Inglis, Carey put Australia in command of South Africa decider
-
Bolsonaro flees Brazil for US after election defeat
-
French firm Safran helps build aircraft wings of the future in UK factory
-
A throne on wheels, popemobiles star in new Vatican show
-
Ceasefire in Russia-occupied Ukrainian city holds for second day
Ozempic slimming craze sweeps Kosovo despite side effects
Kosovo influencer Tringa Kadriu sees the slimming drug Ozempic as a chance to shed excess pounds -- and she is not the only one in her Balkan nation, where more than half the population is overweight.
"I want to lose 15-16 kilos (33-35 pounds) in two months," Kadriu, 29, told AFP, "and then I'll continue with fitness".
Ozempic, approved in the United States to treat diabetes in 2017, has found an international market for people trying to lose weight.
Despite its cost, the drug has soared in popularity in Kosovo, a country of 1.7 million.
While Kosovo authorities have not sanctioned the drug's use for weight loss, they have noted their limited means to confront use of a drug widely available in the country.
Merita Emini-Sadiku, who heads the Kosovo university hospital's endocrinology clinic, said the cost of the drug had soared.
"The monthly dose used to be 75-80 euros ($85-91), while now it is 130-140 euros ($147-159), probably due to high demand," she said.
But she warned that "Ozempic has side effects that people are not aware of".
Ozempic use can potentially cause issues including thyroid cancer, pancreatitis, gastroparesis and bowel obstruction, according to the latest studies.
- 'Constant demand' -
Meant to treat Type 2 diabetes -- of which the WHO says Kosovo has lower than average levels -- the drug regulates blood sugar levels but also helps suppress hunger, leading to a lower calorie intake.
As a result, its potentially cancerous complications have done little to stem the drug's popularity or availability.
"I checked a lot of pharmacies in Kosovo and I noticed that Ozempic is very easy to get," said Kadriu, adding that pharmacists even suggested she gradually increase her dosage.
A worker at a pharmacy in the capital Pristina's downtown, who asked to remain anonymous, said she had trouble recalling when someone last came into her pharmacy to buy Ozempic with a diabetes prescription.
"But we have a constant demand for Ozempic without a prescription. You can guess why," she said.
Given its availability, Emini-Sadiku said authorities should exercise greater control over Ozempic's distribution.
But Bujar Vitija, a journalist specialising in health, said that would be tricky to achieve given Kosovo's poor health record-keeping.
"Unfortunately there is no data," Vitija said.
With 1,500 to 1,600 private pharmacies in Kosovo, the country's 20 pharmaceutical inspectors have their work cut out for them, he added.
- Ozempic 'every day' -
While Kosovo has lower levels of obesity than the European average, more than 57 percent of the population is overweight and 20 percent is clinically obese, according to a 2019 World Health Organization report.
And women, who are more likely to face societal pressure to be thin, were 66 percent more likely to be obese than men, the WHO report found.
But not every Kosovar who has used Ozempic had the best experience with the drug.
"I took Ozempic on the advice of a doctor for two years but it had no effect," said 48-year-old merchant Lulzim Rrahmani, adding that three of his relatives even experienced "a negative effect of the drug".
"It was just a waste of money and time."
Given the risk of side effects, Emini-Sadiku said Ozempic was "by no means to be taken without a doctor's prescription".
Yet Kadriu said she would not be deterred, adding that she saw colleagues taking the drug "every day at work".
"I don't see any symptom that would deter me."
N.Schaad--VB